151 related articles for article (PubMed ID: 27758825)
1. Absence of CALR mutations in JAK2-negative polycythemia.
Chauveau A; Nibourel O; Tondeur S; Luque Paz D; Mansier O; Paul F; Wemeau M; Preudhomme C; Lippert E; Ugo V;
Haematologica; 2017 Jan; 102(1):e15-e16. PubMed ID: 27758825
[No Abstract] [Full Text] [Related]
2. Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the
Brusson M; Cochet S; Leduc M; Guillonneau F; Mayeux P; Peyrard T; Chomienne C; Le Van Kim C; Cassinat B; Kiladjian JJ; El Nemer W
Haematologica; 2017 Jul; 102(7):e241-e244. PubMed ID: 28385780
[No Abstract] [Full Text] [Related]
3. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
4. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
5. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
6. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of JAK2 V617F and an uncommon CALR del (p.K368fs*51) mutation facilitates JAK2/STAT signaling in polycythemia vera.
Xing CY; Li HY; Wu JB; Gao SM
Leuk Lymphoma; 2016 Jul; 57(7):1743-5. PubMed ID: 26701108
[No Abstract] [Full Text] [Related]
9. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
[TBL] [Abstract][Full Text] [Related]
10. Progression of
Holmström MO; Novotny GW; Petersen J; Aaboe-Jørgensen M; Hasselbalch HC; Andersen MH; Nielsen SL; Fassi DE; Schöllkopf C
Leuk Lymphoma; 2019 Dec; 60(13):3296-3299. PubMed ID: 31256699
[No Abstract] [Full Text] [Related]
11. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
12. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Giraldo-Rincón AI; Naranjo Molina S; Gomez-Lopera N; Aguirre Acevedo D; Ucroz Benavidez A; Gálvez Cárdenas K; Cuellar Ambrosí F; Torres JD; Ospina S; Palacio K; Gaviria Jaramillo L; Muñeton CM; Vasquez Palacio G
Colomb Med (Cali); 2023; 54(3):e2035353. PubMed ID: 38111518
[TBL] [Abstract][Full Text] [Related]
13. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
[TBL] [Abstract][Full Text] [Related]
15. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
[TBL] [Abstract][Full Text] [Related]
16. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
17. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
[No Abstract] [Full Text] [Related]
18. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
[TBL] [Abstract][Full Text] [Related]
19. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
20. The Calreticulin gene and myeloproliferative neoplasms.
Clinton A; McMullin MF
J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
